Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
PyroGenesis Canada Inc. stock logo
PYRGF
PyroGenesis Canada
$0.34
+2.4%
$0.34
$0.30
$0.80
$63.64M0.8411,194 shs13,110 shs
resTORbio, Inc. stock logo
TORC
resTORbio
$0.61
-1.1%
$12.16
$0.86
$10.50
$22.13M2.431.15 million shs545,982 shs
Viveon Health Acquisition Corp. stock logo
VHAQ
Viveon Health Acquisition
$11.00
$11.00
$0.00
$12.48
$62.26M-0.112 shs99 shs
WHWK
Whitehawk Therapeutics
$1.99
+5.9%
$0.00
$1.21
$3.81
$93.75M0.55132,209 shs57,482 shs
7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025 Cover

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
PyroGenesis Canada Inc. stock logo
PYRGF
PyroGenesis Canada
0.00%+4.09%-7.64%+12.29%-41.02%
resTORbio, Inc. stock logo
TORC
resTORbio
0.00%-2.97%-19.01%-9.54%-43.27%
Viveon Health Acquisition Corp. stock logo
VHAQ
Viveon Health Acquisition
0.00%0.00%0.00%0.00%+10.00%
WHWK
Whitehawk Therapeutics
0.00%+3.11%+198,999,900.00%+198,999,900.00%+198,999,900.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
PyroGenesis Canada Inc. stock logo
PYRGF
PyroGenesis Canada
0.0912 of 5 stars
0.02.00.00.00.01.70.0
resTORbio, Inc. stock logo
TORC
resTORbio
N/AN/AN/AN/AN/AN/AN/AN/A
Viveon Health Acquisition Corp. stock logo
VHAQ
Viveon Health Acquisition
N/AN/AN/AN/AN/AN/AN/AN/A
WHWK
Whitehawk Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
PyroGenesis Canada Inc. stock logo
PYRGF
PyroGenesis Canada
0.00
N/AN/AN/A
resTORbio, Inc. stock logo
TORC
resTORbio
0.00
N/AN/AN/A
Viveon Health Acquisition Corp. stock logo
VHAQ
Viveon Health Acquisition
0.00
N/AN/AN/A
WHWK
Whitehawk Therapeutics
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
PyroGenesis Canada Inc. stock logo
PYRGF
PyroGenesis Canada
$9.14M6.96N/AN/A($0.01) per share-34.09
resTORbio, Inc. stock logo
TORC
resTORbio
N/AN/AN/AN/A$2.24 per shareN/A
Viveon Health Acquisition Corp. stock logo
VHAQ
Viveon Health Acquisition
N/AN/AN/AN/AN/AN/A
WHWK
Whitehawk Therapeutics
$25.98M3.61N/AN/A$2.12 per share0.94
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
PyroGenesis Canada Inc. stock logo
PYRGF
PyroGenesis Canada
-$21.12M-$0.02N/AN/A-115.14%N/A-60.81%N/A
resTORbio, Inc. stock logo
TORC
resTORbio
-$82.74M-$2.41N/AN/AN/AN/A-78.12%-71.63%N/A
Viveon Health Acquisition Corp. stock logo
VHAQ
Viveon Health Acquisition
-$610KN/A0.00N/AN/AN/AN/AN/A
WHWK
Whitehawk Therapeutics
-$63.69M$0.1612.44N/A99.42%-56.73%-48.68%N/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
PyroGenesis Canada Inc. stock logo
PYRGF
PyroGenesis Canada
N/AN/AN/AN/AN/A
resTORbio, Inc. stock logo
TORC
resTORbio
N/AN/AN/AN/AN/A
Viveon Health Acquisition Corp. stock logo
VHAQ
Viveon Health Acquisition
N/AN/AN/AN/AN/A
WHWK
Whitehawk Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
PyroGenesis Canada Inc. stock logo
PYRGF
PyroGenesis Canada
N/A
0.60
0.50
resTORbio, Inc. stock logo
TORC
resTORbio
N/A
20.69
20.69
Viveon Health Acquisition Corp. stock logo
VHAQ
Viveon Health Acquisition
N/AN/AN/A
WHWK
Whitehawk Therapeutics
N/A
18.95
18.95

Institutional Ownership

CompanyInstitutional Ownership
PyroGenesis Canada Inc. stock logo
PYRGF
PyroGenesis Canada
0.03%
resTORbio, Inc. stock logo
TORC
resTORbio
46.19%
Viveon Health Acquisition Corp. stock logo
VHAQ
Viveon Health Acquisition
22.14%
WHWK
Whitehawk Therapeutics
52.08%

Insider Ownership

CompanyInsider Ownership
PyroGenesis Canada Inc. stock logo
PYRGF
PyroGenesis Canada
47.68%
resTORbio, Inc. stock logo
TORC
resTORbio
11.80%
Viveon Health Acquisition Corp. stock logo
VHAQ
Viveon Health Acquisition
75.27%
WHWK
Whitehawk Therapeutics
49.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
PyroGenesis Canada Inc. stock logo
PYRGF
PyroGenesis Canada
90186.69 million96.34 millionNo Data
resTORbio, Inc. stock logo
TORC
resTORbio
N/A36.45 millionN/ANot Optionable
Viveon Health Acquisition Corp. stock logo
VHAQ
Viveon Health Acquisition
25.66 million1.40 millionNot Optionable
WHWK
Whitehawk Therapeutics
4047.11 million23.60 millionN/A

Recent News About These Companies

No headlines for this company have been tracked by MarketBeat.com

Media Sentiment Over Time

PyroGenesis Canada stock logo

PyroGenesis Canada NASDAQ:PYRGF

$0.34 +0.01 (+2.37%)
As of 07/3/2025 12:24 PM Eastern

PyroGenesis Canada Inc. designs, develops, manufactures, and commercializes plasma processes and solutions worldwide. The company offers DROSRITE, a process for enhancing metal recovery from dross without any hazardous by-products; plasma atomization process that allows produce and sell high purity spherical metal powders; PUREVAP, a process to produce high purity metallurgical and solar grade silicon from quartz; and PUREVAP NSiR, which is designed to transform silicon into spherical silicon nano powders and nanowires for use in lithium-ion batteries. It provides plasma torches and plasma torch systems used toreplace fossil fuel burners in industrial iron ore pelletization process; plasma arc waste destruction systems for waste destruction onboard ships; steam plasma arc refrigerant cracking systems for the destruction of certain refrigerants, including chlorofluorocarbons, hydrofluorocarbons, and hydrochlorofluorocarbons; plasma arc chemical warfare agent destruction systems, which are mobile platforms for the onsite destruction of chemical warfare agents; plasma resource recovery systems for land-based waste destruction and waste-to-energy applications; plasma torches for waste gasification and combustion; and plasma arc gasification and vitrification. In addition, it offers engineering and manufacturing expertise, and contract research, as well as turnkey process equipment packages to the defense, metallurgical, mining, additive manufacturing (including 3D printing), oil and gas, and environmental industries. Further, the company provides installation, commissioning, and start-up services. PyroGenesis Canada Inc. is headquartered in Montreal, Canada.

resTORbio stock logo

resTORbio NASDAQ:TORC

Adicet Bio, Inc. is a biotechnology company which engages in the design and development of off-the-shelf allogeneic gamma delta T cell therapies for cancer and other diseases. The company was founded by Aya Jakobovits in November 2014 and is headquartered in Boston, MA.

Viveon Health Acquisition stock logo

Viveon Health Acquisition NYSE:VHAQ

$11.00 0.00 (0.00%)
As of 01/30/2025

Viveon Health Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or similar business combination with one or more businesses in the healthcare industry in North America. The company was incorporated in 2020 and is based in Atlanta, Georgia. Viveon Health Acquisition Corp. operates as a subsidiary of Viveon Health LLC.

Whitehawk Therapeutics NASDAQ:WHWK

$1.99 +0.11 (+5.85%)
As of 07/3/2025 01:00 PM Eastern

Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.